ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
항체 단편 시장 규모는 향후 몇 년간 강력한 성장이 예상될 예정입니다. 자가면역질환에의 응용 확대, 이중 특이성 항체의 출현 등에 기인하는 것으로 예측됩니다.
대상 질환의 유병률 상승은 향후 수 년간 항체 단편 시장의 성장을 견인할 것으로 예측됩니다. 일반적인 대상 질환으로는 암, 감염증, 세균 감염증 등이 있습니다. 건강 문제의 한 원인이 되고 있습니다. 항체 단편은 다양한 질환에 대해 매우 특이적이고 적당한 다용도의 치료법을 제공하며, 많은 경우 기존의 치료법에 비해 부작용이 적은 것이 특징입니다. 특정 목표에 맞게 설계할 수 있기 때문에 현대 의학에서 매우 귀중한 도구가 되고 있습니다.
American Cancer Society(미국암협회)는 2025년에는 미국에서 새롭게 204만 1,910명의 암 환자 발생과 61만 8,120명의 암 관련 사망이 발생할 것으로 예상되며, 이는 2024년 신규 환자수 200만 1,140명, 사망자 수 61만 1,720명 보다 증가한 수치라고 보고했습니다. 이와 같이, 대상 질환의 유병률 증가가 항체 단편 시장의 확대에 박차를 가하고 있습니다.
항체 단편 시장의 주요 기업은 인간 VH 항체 단편과 같은 혁신적인 제품을 개발하기 위한 임상시험의 실시에 주력하고 있으며, 암, 자가면역 질환, 감염증의 치료에 있어서 표적 요법의 효능을 향상시키고, 면역원성을 저감시키는 것을 목표로 하고 있습니다. 중쇄의 가변 도메인으로, 독립적으로 항원에 결합할 수 있습니다. 중요한 항원 결합 영역으로서 기능하는 것으로 항체 단편을 형성해, 소형이고 안정한 고친화성의 치료 및 진단용 항체를 제작하기 위해, 단독 또는 다른 분자와 조합해 사용됩니다. 2024년 5월, 중국에 본사를 둔 제약 회사인 자이 랩(Zai Lab Limited)은 IL-17을 표적으로 하는 새로운 인간 VH 항체 단편(Humabody)인 ZL-1102의 효능과 안전성을 평가하는 국제 공동 2상 임상시험을 시작했습니다. 이 치료는 경도에서 중등도의 만성 심상성 건선에 대한 외용 요법으로 개발되어 전신성 부작용과 면역원성 반응을 최소화하면서 치료 정밀도 향상을 목표로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 태와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 항체 단편 시장의 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 항체 단편 시장 : 성장률 분석
세계의 항체 단편 시장 실적 : 규모와 성장, 2019-2024년
세계의 항체 단편 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 항체 단편 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 항체 단편 시장 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
F(ab)단편
F(ab')2 단편
단쇄 가변 단편(scFv)
단일 도메인 항체 단편(sdAbs)
기타
세계의 항체 단편 시장 : 특이성별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
단일클론항체
폴리클로날 항체
세계의 항체 단편 시장 : 투여 방법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
정맥내(IV)
피하(SC)
경구
경피
세계의 항체 단편 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
암
면역 결핍
기타
세계의 항체 단편 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제약회사
바이오테크놀러지 기업
연구기관
진단실험실
계약연구기관(CRO)
세계의 항체 단편 시장 : F(ab) 단편의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
재조합 F(ab) 단편
효소 유도 F(ab) 단편
세계의 항체 단편 시장 : F(ab')2 단편의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
펩신 유래 F(ab')2 단편
재조합 F(ab')2 단편
세계의 항체 단편 시장 : 단쇄 가변 단편(scFv)의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세균 생산 단쇄 가변 단편(scFv)
포유류 세포 생산 단쇄 가변 단편(scFv)
효모 생산 단쇄 가변 단편(scFv)
세계의 항체 단편 시장 : 단일 도메인 항체 단편(sdAbs)의 세분화: 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
낙타과 동물 유래 단일 도메인 항체 단편(sdAbs)
상어 유래 단일 도메인 항체 단편(sdAbs)
합성 단일 도메인 항체 단편(sdAbs)
세계의 항체 단편 시장 : 기타 세분화 : 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
이중특이적 항체 단편
다중특이적 항체 단편
융합 단백질 항체 단편
제7장 지역별/국가별 분석
세계의 항체 단편 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 항체 단편 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
항체 단편 시장 : 경쟁 구도
항체 단편 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AstraZeneca PLC
Novartis AG
GSK plc
Eli Lilly and Company
Amgen Inc.
Boehringer Ingelheim International GmbH
Regeneron Pharmaceuticals Inc.
Biogen Inc.
UCB SA
Bio-Rad Laboratories Inc.
Genmab A/S
WuXi Biologics Co. Ltd.
Abcam plc
MacroGenics Inc.
Harbour BioMed
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
항체 단편 시장 2029 : 새로운 기회를 제공하는 국가
항체 단편 시장 2029 : 새로운 기회를 제공하는 부문
항체 단편 시장 2029 : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Antibody fragments are smaller portions of full-length antibodies that retain the ability to bind to specific antigens. These fragments are derived from antibodies and are designed to offer advantages such as greater stability, better tissue penetration, and reduced immune system reactions, making them valuable for both therapeutic and diagnostic uses.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main types of antibody fragments include F(ab) fragments, F(ab')2 fragments, single-chain variable fragments (scFvs), single-domain antibody fragments (sdAbs), and other types. F(ab) fragments are specific fragments that have a single antigen-binding site, lacking the Fc region to minimize immune interactions, which enhances their use in diagnostics and therapy. Antibody fragments can be classified as either monoclonal or polyclonal antibodies based on their specificity. These fragments are administered through various methods, including intravenous (IV), subcutaneous (SC), oral, or transdermal routes. They are used for treating conditions such as cancer, immunodeficiencies, and other medical disorders. The key end users of antibody fragments include pharmaceutical companies, biotechnology firms, research institutions, diagnostic labs, and contract research organizations (CROs).
The antibody fragments market research report is one of a series of new reports from The Business Research Company that provides antibody fragments market statistics, including the antibody fragments industry global market size, regional shares, competitors with the antibody fragments market share, detailed antibody fragments market segments, market trends, and opportunities, and any further data you may need to thrive in the antibody fragments industry. This antibody fragments market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The antibody fragments market size has grown strongly in recent years. It will grow from $10.35 billion in 2024 to $11.37 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to the rising prevalence of chronic diseases, increased adoption of biologics, growth in cancer therapeutics, regulatory approvals for antibody-based treatments, and the expansion of biopharmaceutical research.
The antibody fragments market size is expected to see strong growth in the next few years. It will grow to $16.44 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to increasing investment in research and development of biologics, growing preference for smaller antibody formats, rising demand for personalized medicine, expanding applications in autoimmune diseases, and the emergence of bispecific antibodies. Major trends in the forecast period include the integration of AI-driven drug discovery, development of cost-effective production methods, collaborations between biotech firms, advancements in monoclonal antibody technology, and a focus on antibody-drug conjugates.
The rising prevalence of target diseases is expected to drive the growth of the antibody fragments market in the coming years. Target diseases refer to specific conditions or illnesses that medical treatments, therapies, or research aim to prevent, manage, or cure. Common target diseases include cancer, infectious diseases, and bacterial infections. The increasing prevalence of these diseases is primarily attributed to unhealthy lifestyles and pollution, which weaken the body's defenses and contribute to chronic health issues. Antibody fragments offer highly specific, targeted, and versatile treatment options for a variety of diseases, often with fewer side effects compared to traditional therapies. Their ability to be tailored and engineered for specific targets makes them an invaluable tool in modern medicine. For example, in January 2025, the American Cancer Society, a U.S.-based nonprofit organization, reported that in 2025, the United States is expected to see 2,041,910 new cancer cases and 618,120 cancer-related deaths, up from 2,001,140 new cases and 611,720 deaths in 2024. Thus, the growing prevalence of target diseases is fueling the antibody fragments market's expansion.
Leading companies in the antibody fragments market are focusing on conducting clinical trials to develop innovative products, such as human VH antibody fragments, to improve the effectiveness of targeted therapies and reduce immunogenicity when treating cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is the variable domain of the heavy chain of a human antibody, capable of binding to antigens independently. It forms antibody fragments by serving as the crucial antigen-binding region and is often used alone or in combination with other molecules to create small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a China-based pharmaceutical company, initiated a global Phase 2 clinical trial to assess the efficacy and safety of ZL-1102, a novel human VH antibody fragment (Humabody) targeting IL-17. This treatment is being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis, aimed at improving treatment precision while minimizing systemic side effects and immunogenic responses.
In September 2024, Valerio Therapeutics S.A., a clinical-stage biotechnology company based in France, acquired Emglev Therapeutics for an undisclosed sum. This acquisition enhances Valerio Therapeutics' antibody discovery capabilities by incorporating Emglev Therapeutics' synthetic single-domain antibody (sdAb) technology, further expanding its therapeutic applications. Emglev Therapeutics is a biotechnology firm based in France, specializing in the development of synthetic single-domain antibodies (sdAb).
Major players in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.
North America was the largest region in the antibody fragments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antibody fragments report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the antibody fragments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The antibody fragments market consists of revenues earned by entities by providing services such as pharmacokinetics and toxicology testing, clinical and regulatory support services, custom conjugation services, and antibody fragment production and expression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The antibody fragments market also includes sales of diabodies and tribodies, nanobodies, antibody-based therapeutics, and diagnostic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Antibody Fragments Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on antibody fragments market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for antibody fragments ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antibody fragments market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: F(ab) Fragments; F(ab')2 Fragments; Single-Chain Variable Fragments (scFvs); Single Domain Antibody Fragments (sdAbs); Other Types
2) By Specificity: Monoclonal Antibody; Polyclonal Antibody
3) By Delivery Method: Intravenous (IV); Subcutaneous (SC); Oral; Transdermal
4) By Application: Cancer; Immunodeficiencies; Other Applications
5) By End User: Pharmaceutical Companies; Biotechnology Companies; Research Institutions; Diagnostic Laboratories; Contract Research Organizations (CROs)
4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs); Shark-Derived Single Domain Antibody Fragments (sdAbs); Synthetic Single Domain Antibody Fragments (sdAbs)
5) By Other Types: Bispecific Antibody Fragments; Multispecific Antibody Fragments; Fusion Protein Antibody Fragments
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Sanofi S.A.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Antibody Fragments Market Characteristics
3. Antibody Fragments Market Trends And Strategies
4. Antibody Fragments Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Antibody Fragments Growth Analysis And Strategic Analysis Framework
5.1. Global Antibody Fragments PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Antibody Fragments Market Growth Rate Analysis
5.4. Global Antibody Fragments Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Antibody Fragments Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Antibody Fragments Total Addressable Market (TAM)
6. Antibody Fragments Market Segmentation
6.1. Global Antibody Fragments Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
F(ab) Fragments
F(ab')2 Fragments
Single-Chain Variable Fragments (scFvs)
Single Domain Antibody Fragments (sdAbs)
Other Types
6.2. Global Antibody Fragments Market, Segmentation By Specificity, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody
Polyclonal Antibody
6.3. Global Antibody Fragments Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV)
Subcutaneous (SC)
Oral
Transdermal
6.4. Global Antibody Fragments Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cancer
Immunodeficiencies
Other Applications
6.5. Global Antibody Fragments Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Biotechnology Companies
Research Institutions
Diagnostic Laboratories
Contract Research Organizations (CROs)
6.6. Global Antibody Fragments Market, Sub-Segmentation Of F(ab) Fragments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant F(ab) Fragments
Enzymatically Derived F(ab) Fragments
6.7. Global Antibody Fragments Market, Sub-Segmentation Of F(ab')2 Fragments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pepsin-Derived F(ab')2 Fragments
Recombinant F(ab')2 Fragments
6.8. Global Antibody Fragments Market, Sub-Segmentation Of Single-Chain Variable Fragments (scFvs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.9. Global Antibody Fragments Market, Sub-Segmentation Of Single Domain Antibody Fragments (sdAbs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Camelid-Derived Single Domain Antibody Fragments (sdAbs)
Shark-Derived Single Domain Antibody Fragments (sdAbs)
Synthetic Single Domain Antibody Fragments (sdAbs)
6.10. Global Antibody Fragments Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bispecific Antibody Fragments
Multispecific Antibody Fragments
Fusion Protein Antibody Fragments
7. Antibody Fragments Market Regional And Country Analysis
7.1. Global Antibody Fragments Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Antibody Fragments Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
